Bristol Myers Squibb Cash on Hand 2010-2023 | BMY
Bristol Myers Squibb cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Bristol Myers Squibb cash on hand for the quarter ending March 31, 2023 was $9.269B, a 38.07% decline year-over-year.
- Bristol Myers Squibb cash on hand for 2022 was $9.253B, a 45.46% decline from 2021.
- Bristol Myers Squibb cash on hand for 2021 was $16.966B, a 7.17% increase from 2020.
- Bristol Myers Squibb cash on hand for 2020 was $15.831B, a 2.85% increase from 2019.
Bristol Myers Squibb Annual Cash on Hand
(Millions of US $) |
| 2022 |
$9,253 |
| 2021 |
$16,966 |
| 2020 |
$15,831 |
| 2019 |
$15,393 |
| 2018 |
$8,759 |
| 2017 |
$6,812 |
| 2016 |
$6,350 |
| 2015 |
$4,270 |
| 2014 |
$7,435 |
| 2013 |
$4,525 |
| 2012 |
$2,829 |
| 2011 |
$8,733 |
| 2010 |
$7,301 |
| 2009 |
$8,514 |
Bristol Myers Squibb Quarterly Cash on Hand
(Millions of US $) |
| 2023-03-31 |
$9,269 |
| 2022-12-31 |
$9,253 |
| 2022-09-30 |
$9,027 |
| 2022-06-30 |
$13,228 |
| 2022-03-31 |
$14,968 |
| 2021-12-31 |
$16,966 |
| 2021-09-30 |
$15,663 |
| 2021-06-30 |
$12,970 |
| 2021-03-31 |
$12,930 |
| 2020-12-31 |
$15,831 |
| 2020-09-30 |
$21,155 |
| 2020-06-30 |
$21,658 |
| 2020-03-31 |
$18,322 |
| 2019-12-31 |
$15,393 |
| 2019-09-30 |
$32,542 |
| 2019-06-30 |
$29,357 |
| 2019-03-31 |
$8,764 |
| 2018-12-31 |
$8,759 |
| 2018-09-30 |
$6,830 |
| 2018-06-30 |
$6,075 |
| 2018-03-31 |
$6,770 |
| 2017-12-31 |
$6,812 |
| 2017-09-30 |
$7,122 |
| 2017-06-30 |
$6,505 |
| 2017-03-31 |
$6,109 |
| 2016-12-31 |
$6,350 |
| 2016-09-30 |
$5,560 |
| 2016-06-30 |
$4,651 |
| 2016-03-31 |
$4,307 |
| 2015-12-31 |
$4,270 |
| 2015-09-30 |
$5,413 |
| 2015-06-30 |
$5,476 |
| 2015-03-31 |
$7,607 |
| 2014-12-31 |
$7,435 |
| 2014-09-30 |
$7,221 |
| 2014-06-30 |
$7,175 |
| 2014-03-31 |
$7,059 |
| 2013-12-31 |
$4,525 |
| 2013-09-30 |
$2,722 |
| 2013-06-30 |
$2,799 |
| 2013-03-31 |
$2,533 |
| 2012-12-31 |
$2,829 |
| 2012-09-30 |
$2,930 |
| 2012-06-30 |
$5,037 |
| 2012-03-31 |
$5,029 |
| 2011-12-31 |
$8,733 |
| 2011-09-30 |
$8,193 |
| 2011-06-30 |
$7,670 |
| 2011-03-31 |
$6,793 |
| 2010-12-31 |
$7,301 |
| 2010-09-30 |
$8,359 |
| 2010-06-30 |
$7,454 |
| 2010-03-31 |
$6,776 |
| 2009-12-31 |
$8,514 |
| 2009-09-30 |
$6,669 |
| 2009-06-30 |
$8,120 |
| 2009-03-31 |
$8,920 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$135.379B |
$46.159B |
|
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
|
